Does the media prefer EXEL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Exelixis. MarketBeat recorded 15 mentions for Alnylam Pharmaceuticals and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Alnylam Pharmaceuticals' score of 0.58 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, BIIB or EXEL?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.07 $1.29B $9.32 22.10 Exelixis $2.32B 6.06 $782.57M $3.01 18.58

Is BIIB or EXEL more profitable?

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 13.81% 12.83% 8.01% Exelixis 35.08% 39.89% 30.23%

Does the media prefer BIIB or EXEL?

In the previous week, Biogen had 50 more articles in the media than Exelixis. MarketBeat recorded 60 mentions for Biogen and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Biogen's score of 0.82 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 31 Very Positive mention(s) 7 Positive mention(s) 14 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, EXEL or INCY?

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.06 $782.57M $3.01 18.58 Incyte $5.14B 4.56 $1.29B $7.08 16.56

Is EXEL or INCY more profitable?

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.08% 39.89% 30.23% Incyte 26.71% 26.66% 19.77%

Does the media favor EXEL or INCY?

In the previous week, Incyte had 16 more articles in the media than Exelixis. MarketBeat recorded 26 mentions for Incyte and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Incyte's score of 0.95 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 14 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to UTHR or EXEL?

In the previous week, United Therapeutics had 10 more articles in the media than Exelixis. MarketBeat recorded 20 mentions for United Therapeutics and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat United Therapeutics' score of 1.03 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 15 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NBIX or EXEL?

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Exelixis. MarketBeat recorded 19 mentions for Neurocrine Biosciences and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Neurocrine Biosciences' score of 0.82 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$55.92 +0.24 (+0.43%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$55.80 -0.12 (-0.21%)

As of 07/17/2026 07:57 PM Eastern

Compare

EXEL vs. ALNY, BIIB, INCY, UTHR, and NBIX

Should you buy Exelixis stock or one of its competitors? MarketBeat compares Exelixis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Alnylam Pharmaceuticals?

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.08% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Exelixis currently has a consensus price target of $48.80, indicating a potential downside of 12.73%. Alnylam Pharmaceuticals has a consensus price target of $455.31, indicating a potential upside of 70.23%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.06	$782.57M	$3.01	18.58
Alnylam Pharmaceuticals	$3.71B	9.62	$313.75M	$3.66	73.08

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Exelixis. MarketBeat recorded 15 mentions for Alnylam Pharmaceuticals and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Alnylam Pharmaceuticals' score of 0.58 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

87.9% of Biogen shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.07	$1.29B	$9.32	22.10
Exelixis	$2.32B	6.06	$782.57M	$3.01	18.58

Biogen has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Exelixis	35.08%	39.89%	30.23%

In the previous week, Biogen had 50 more articles in the media than Exelixis. MarketBeat recorded 60 mentions for Biogen and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Biogen's score of 0.82 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	31 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen presently has a consensus target price of $220.04, suggesting a potential upside of 6.82%. Exelixis has a consensus target price of $48.80, suggesting a potential downside of 12.73%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Exelixis	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35

Summary

Biogen beats Exelixis on 10 of the 17 factors compared between the two stocks.

How does Exelixis compare to Incyte?

Exelixis (NASDAQ:EXEL) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Incyte	26.71%	26.66%	19.77%

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.06	$782.57M	$3.01	18.58
Incyte	$5.14B	4.56	$1.29B	$7.08	16.56

In the previous week, Incyte had 16 more articles in the media than Exelixis. MarketBeat recorded 26 mentions for Incyte and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Incyte's score of 0.95 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	14 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis presently has a consensus price target of $48.80, suggesting a potential downside of 12.73%. Incyte has a consensus price target of $109.95, suggesting a potential downside of 6.23%. Given Incyte's stronger consensus rating and higher possible upside, analysts clearly believe Incyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36

Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Incyte beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Exelixis' net margin of 35.08%. Exelixis' return on equity of 39.89% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Exelixis	35.08%	39.89%	30.23%

United Therapeutics has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.17B	7.17	$1.33B	$27.09	19.77
Exelixis	$2.32B	6.06	$782.57M	$3.01	18.58

United Therapeutics currently has a consensus price target of $644.82, indicating a potential upside of 20.38%. Exelixis has a consensus price target of $48.80, indicating a potential downside of 12.73%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe United Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Exelixis	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 10 more articles in the media than Exelixis. MarketBeat recorded 20 mentions for United Therapeutics and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat United Therapeutics' score of 1.03 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	15 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Exelixis on 13 of the 16 factors compared between the two stocks.

How does Exelixis compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Neurocrine Biosciences currently has a consensus target price of $192.86, indicating a potential upside of 12.86%. Exelixis has a consensus target price of $48.80, indicating a potential downside of 12.73%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
Exelixis	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35

Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Exelixis	35.08%	39.89%	30.23%

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Exelixis. MarketBeat recorded 19 mentions for Neurocrine Biosciences and 10 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Neurocrine Biosciences' score of 0.82 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has lower revenue, but higher earnings than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	6.01	$478.60M	$6.49	26.33
Exelixis	$2.32B	6.06	$782.57M	$3.01	18.58

Neurocrine Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Exelixis on 10 of the 17 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.00B	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	18.58	20.85	27.14	23.89
Price / Sales	6.06	304.44	524.02	91.05
Price / Cash	18.39	142.33	51.46	60.07
Price / Book	6.94	8.26	10.69	6.18
Net Income	$782.57M	$23.83M	$3.59B	$331.73M
7 Day Performance	-1.03%	-3.48%	-2.17%	-2.09%
1 Month Performance	7.72%	2.58%	1.63%	-2.19%
1 Year Performance	25.75%	45.93%	25.56%	17.20%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	3.6031 of 5 stars	$55.92 +0.4%	$48.80 -12.7%	+24.6%	$14.00B	$2.32B	18.58	1,077	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.1479 of 5 stars	$281.26 -2.4%	$455.31 +61.9%	-17.6%	$37.55B	$4.29B	76.85	2,770	Analyst Forecast Analyst Revision
BIIB Biogen	3.5476 of 5 stars	$191.95 -8.2%	$220.04 +14.6%	+60.1%	$28.34B	$9.94B	20.60	7,500	Analyst Forecast High Trading Volume
INCY Incyte	2.8443 of 5 stars	$114.88 +0.6%	$109.95 -4.3%	+70.1%	$22.95B	$5.14B	16.23	2,844	News Coverage Analyst Forecast
UTHR United Therapeutics	4.5798 of 5 stars	$526.66 -1.7%	$644.82 +22.4%	+80.2%	$22.36B	$3.18B	19.44	1,400	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to Incyte?

Summary

How does Exelixis compare to United Therapeutics?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Do insiders and institutionals believe in EXEL or ALNY?

Is EXEL or ALNY more profitable?

Which has more volatility and risk, EXEL or ALNY?

Do analysts rate EXEL or ALNY?

Which has higher earnings and valuation, EXEL or ALNY?

Does the media prefer EXEL or ALNY?

Summary

How does Exelixis compare to Biogen?

Do institutionals and insiders hold more shares of BIIB or EXEL?

Which has higher earnings & valuation, BIIB or EXEL?

Which has more volatility and risk, BIIB or EXEL?

Is BIIB or EXEL more profitable?

Does the media prefer BIIB or EXEL?

Do analysts prefer BIIB or EXEL?

Summary

How does Exelixis compare to Incyte?

Do institutionals and insiders hold more shares of EXEL or INCY?

Is EXEL or INCY more profitable?

Which has stronger earnings and valuation, EXEL or INCY?

Does the media favor EXEL or INCY?

Do analysts rate EXEL or INCY?

Which has more risk and volatility, EXEL or INCY?

Summary

How does Exelixis compare to United Therapeutics?

Which has more volatility and risk, UTHR or EXEL?

Is UTHR or EXEL more profitable?

Which has preferable earnings & valuation, UTHR or EXEL?

Do analysts rate UTHR or EXEL?

Do insiders & institutionals have more ownership in UTHR or EXEL?

Does the media refer more to UTHR or EXEL?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Do analysts prefer NBIX or EXEL?

Is NBIX or EXEL more profitable?

Does the media favor NBIX or EXEL?

Which has higher earnings and valuation, NBIX or EXEL?

Which has more risk & volatility, NBIX or EXEL?

Do insiders & institutionals believe in NBIX or EXEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools